Peatonide, marketed by San Marino-based complement firm Pharmaluce “could also be a promising adjunctive strategy for migraine administration,” wrote the researchers from the College of Naples and the Interuniversity Consortium of Biostructures and Biosystems in Rome.
They famous that current non-specific migraine medicines, similar to antiepileptic medication, antidepressants and beta-blockers might have quite a few side effects, making it difficult for sufferers to proceed therapy.
Extra particular drug remedies authorised in recent times might have fewer unwanted side effects, however docs might solely prescribe them to sufferers with debilitating common assaults, suggesting a necessity for pure therapies for people with low-frequency episodic migraine.
Potential mechanisms
Peatonide combines palmitoylethanolamide (PEA) and melatonin.
PEA, studied for its anti-inflammatory, analgesic and immunoregulatory effects, is synthesized within the mind and is often upregulated in diseased states. Its neuroprotective properties are associated to will increase in peroxisome proliferator-activated receptor (PPAR) alpha. Moreover, it reduces NF-kB activation and inhibits mast cell degranulation, which might lower the irritation related to migraine.
Headache problems have a multifactorial and complicated relationship with circadian rhythms and sleep disturbance. The present examine famous that melatonin might lower vasodilation and regulate a number of pathways concerned in triggering migraines, “together with GABA, opioid, serotonergic, adrenergic, cholinergic and melatonergic receptors.”
As well as, melatonin, like PEA, is concerned in mast cell degranulation.
“Due to this fact, the mixture of the 2 molecules may enhance the potential anti-migraine exercise by way of a synergistic impact,” the researchers wrote.
Examine particulars
The randomized, double-blind, placebo-controlled trial recruited 60 women and men who had been identified with episodic migraines with or with out aura for no less than a 12 months earlier than recruitment and skilled no less than two migraine assaults for at least three months previous to the examine.
The researchers assigned individuals to devour both a Peatonide complement (1,200 mg of hydrodispersible PEA and 0.2 mg of melatonin) or placebo at bedtime for 3 months. They have been additionally permitted to take acetaminophen and NSAIDs as wanted for acute part migraine assaults.
Signs have been evaluated utilizing a self-reported each day headache diary.
Outcomes revealed that 27% of these handled with Peatonide had an no less than 50% discount in month-to-month migraine days (MMDs), and 25% had no less than a 50% discount in analgesic use and the length of assaults after three months. No vital variation in MMDs or remedy was noticed within the placebo group.
The examine famous that the complement considerably decreased the frequency, length, depth, incapacity and incidence of related signs. Moreover, no hostile results have been noticed.
Whereas the researchers contemplate the outcomes promising, they famous the small pattern measurement and referred to as for additional large-scale and multi-center trials to verify the complement’s scientific applicability in broader populations.
Supply: Frontiers in Diet. doi: 10.3389/fnut.2025.1560654. “Mounted mixture of palmitoylethanolamide and melatonin in preventive remedy of migraine: outcomes from a randomized scientific trial”. Authors: V. Piccolo et al.
